SAB Biotherapeutics Dirección
Dirección controles de criterios 2/4
El CEO de SAB Biotherapeutics es Samuel Reich , nombrado en Jan 2024, tiene una permanencia de 2.42 años. compensación anual total es $9.43M, compuesta por 5.6% salario y 94.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.031% de las acciones de la empresa, por valor de $74.45K. La antigüedad media del equipo directivo y de la junta directiva es de 3.2 años y 4.9 años, respectivamente.
Información clave
Samuel Reich
Chief Executive Officer (CEO)
US$9.4m
Compensación total
| Porcentaje del salario del CEO | 5.56% |
| Permanencia del CEO | 2.4yrs |
| Participación del CEO | 0.03% |
| Permanencia media de la dirección | 3.2yrs |
| Promedio de permanencia en la Junta Directiva | 4.9yrs |
Actualizaciones recientes de la dirección
Recent updates
Is SAB Biotherapeutics (NASDAQ:SABS) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Autoimmune Disease Modifying Therapies And Regulatory Tailwinds Will Support Long Term Upside Potential
Catalysts About SAB Biotherapeutics SAB Biotherapeutics is a clinical stage biopharmaceutical company developing fully human anti thymocyte immunoglobulin, led by SAB 142 for autoimmune type 1 diabetes. What are the underlying business or industry changes driving this perspective?We Think SAB Biotherapeutics (NASDAQ:SABS) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Improved Revenues Required Before SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock's 42% Jump Looks Justified
SAB Biotherapeutics, Inc. ( NASDAQ:SABS ) shareholders are no doubt pleased to see that the share price has bounced 42...Analysts Are Betting On SAB Biotherapeutics, Inc. (NASDAQ:SABS) With A Big Upgrade This Week
SAB Biotherapeutics, Inc. ( NASDAQ:SABS ) shareholders will have a reason to smile today, with the analysts making...Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues
Shareholders in SAB Biotherapeutics, Inc. ( NASDAQ:SABS ) may be thrilled to learn that the analysts have just...Earnings Beat: SAB Biotherapeutics, Inc. (NASDAQ:SABS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
SAB Biotherapeutics, Inc. ( NASDAQ:SABS ) missed earnings with its latest third-quarter results, disappointing...SAB Bio rises as H1N1 influenza and COVID-19 treatments show efficacy in trial
SAB Biotherapeutics (NASDAQ:SABS) is trading 5.6% higher after the company said its fully-human polyclonal antibody platform maintains efficacy against multiple variants of several highly mutating viruses. A Phase 2a challenge trial showed SAB-176 reduced the viral load in subjects exposed to H1N1 influenza virus and improved symptoms by day four and shortened the timeframe for viral shedding. Another study showed that SAB-185 COVID-19 polyclonal antibody therapeutic candidate was effective in animal models against the majority of known SARS-CoV2 variants.What Does The Future Hold For SAB Biotherapeutics, Inc. (NASDAQ:SABS)? These Analysts Have Been Cutting Their Estimates
The latest analyst coverage could presage a bad day for SAB Biotherapeutics, Inc. ( NASDAQ:SABS ), with the analysts...SAB Biotherapeutics GAAP EPS of -$0.11 beats by $0.03
SAB Biotherapeutics press release (NASDAQ:SABS): Q2 GAAP EPS of -$0.11 beats by $0.03. Cash and cash equivalents were $16.6 million as of June 30, 2022, compared to $22.4 million on March 31, 2022, which was driven primarily by $0.7 million in further capital expansion and SAB’s second quarter cash operating loss of $5.1 million. Financial Guidance: Based on its current operating plans, SAB expects that its existing business plan, cash and cash equivalents, and anticipated cash flows as of June 30, 2022, will be sufficient to fund its operating expenses and capital expenditure requirements for the twelve months following the date our quarterly report on Form 10-Q was made available for issuance.Downgrade: Here's How Analysts See SAB Biotherapeutics, Inc. (NASDAQ:SABS) Performing In The Near Term
Market forces rained on the parade of SAB Biotherapeutics, Inc. ( NASDAQ:SABS ) shareholders today, when the analysts...Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$9m |
| Dec 31 2025 | US$9m | US$525k | US$4m |
| Sep 30 2025 | n/a | n/a | -US$4m |
| Jun 30 2025 | n/a | n/a | -US$20m |
| Mar 31 2025 | n/a | n/a | -US$34m |
| Dec 31 2024 | US$3m | US$518k | -US$34m |
| Sep 30 2024 | n/a | n/a | -US$46m |
| Jun 30 2024 | n/a | n/a | -US$40m |
| Mar 31 2024 | n/a | n/a | -US$40m |
| Dec 31 2023 | US$768k | US$350k | -US$42m |
| Sep 30 2023 | n/a | n/a | -US$27m |
| Jun 30 2023 | n/a | n/a | -US$29m |
| Mar 31 2023 | n/a | n/a | -US$27m |
| Dec 31 2022 | US$985k | US$350k | -US$19m |
| Sep 30 2022 | n/a | n/a | -US$22m |
| Jun 30 2022 | n/a | n/a | -US$19m |
| Mar 31 2022 | n/a | n/a | -US$18m |
| Dec 31 2021 | US$3m | US$53k | -US$17m |
Compensación vs. Mercado: La compensación total de Samuel($USD9.43M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.64M).
Compensación vs. Ingresos: La compensación de Samuel ha aumentado mientras la empresa no es rentable.
CEO
Samuel Reich (51 yo)
Mr. Samuel J. Reich is CEO of SAB Biotherapeutics, Inc. from January 30, 2024 and served as its Chairman and was its Executive Chairman since October 22, 2021 and serves as its Director since October 2021....
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 2.4yrs | US$9.43m | 0.031% $ 74.5k | |
| Co-Founder | 12.4yrs | US$6.11m | 0.74% $ 1.8m | |
| Executive VP & CFO | 1.9yrs | US$2.83m | 0% $ 0 | |
| Executive VP & COO | 4.1yrs | US$1.68m | 0% $ 0 | |
| Executive VP & Chief Medical Officer | 4yrs | US$5.13m | 0.049% $ 117.5k | |
| Vice President of Investor Relations & Corporate Communications | less than a year | sin datos | sin datos | |
| Vice President of Human Resources | no data | sin datos | sin datos | |
| Senior Vice President of Product Development | no data | sin datos | sin datos | |
| Senior Vice President of Regulatory Affairs | 5yrs | sin datos | sin datos | |
| Senior Vice President of Clinical Operations | less than a year | sin datos | sin datos |
Equipo directivo experimentado: El equipo directivo de SABS se considera experimentado (3.2 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 5.6yrs | US$9.43m | 0.031% $ 74.5k | |
| Co-Founder | no data | US$6.11m | 0.74% $ 1.8m | |
| Independent Director | 7.4yrs | US$489.26k | 0% $ 0 | |
| Independent Vice Chairman | 8.4yrs | US$489.26k | 0.0082% $ 19.5k | |
| Independent Director | 3.2yrs | US$496.26k | 0% $ 0 | |
| Independent Chair of the Board | less than a year | sin datos | sin datos | |
| Independent Director | 2.6yrs | US$490.26k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of the Clinical Advisory Board & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board & Member of Clinical Advisory Board | 6.4yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 4.3yrs | sin datos | sin datos |
Junta con experiencia: La junta directiva de SABS se considera experimentada (4.9 años de antigüedad promedio).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/09 16:42 |
| Precio de las acciones al final del día | 2026/06/09 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
SAB Biotherapeutics, Inc. está cubierta por 11 analistas. 8 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Kumaraguru Raja | Brookline Capital Markets |
| Keay Nakae | Chardan Capital Markets, LLC |
| Samantha Lynn Semenkow | Citigroup Inc |